FMP
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
32.72 USD
0 (0%)
Historical Prices
From:
To:
About
ceo
Dr. Jeffrey M. Dayno M.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
CIK
0001802665
ISIN
US4131971040
CUSIP
413197104
Address
630 West Germantown Pike
Phone
484 539 9800
Country
US
Employee
268
IPO Date
Aug 19, 2020
Financial Statement
Earnings
HRMY Financial Summary
CIK
0001802665
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
413197104
ISIN
US4131971040
Country
US
Price
32.72
Beta
0.82
Volume Avg.
633.85k
Market Cap
1.88B
Shares
-
52-Week
28.14-41.61
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
13.04
P/B
-
Website
https://www.harmonybiosciences.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest HRMY News
Alex Lavoie
2 days ago
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Outperforms...
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases. The company is known for its product, WAKIX, which is used to treat excessive daytime sleepiness in adults with narcolepsy. In the competitive landscape, Harmony stands out due to its effective capital utilization, as evidenced by its financial metrics. Harmony Biosciences showcases a Return on Invested Capit...
Danny Green
Mar 4, 2025
Harmony Biosciences Outperforms Peers in Capital Efficiency
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases. The company is known for its innovative approach to addressing unmet medical needs, particularly in the field of sleep disorders. Harmony Biosciences competes with other biotech firms like Inhibrx Biosciences, Kymera Therapeutics, iTeos Therapeutics, Vaxcyte, and Relay Therapeutics. In evaluating Harmony Biosciences, a key...
Gordon Thompson
Feb 24, 2025
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) Quarterly ...
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases. The company is preparing to release its quarterly earnings on February 25, 2025, with Wall Street analysts estimating an earnings per share (EPS) of $0.74 and projected revenue of approximately $201.25 million. Despite a recent setback from the U.S. Food and Drug Administration (FDA), which issued a Refusal...
Zacks Investment Research
Aug 26, 2024
Is Harmony Biosciences (HRMY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PRNewsWire
Aug 21, 2024
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONF...
PLYMOUTH MEETING, Pa. , Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Wells Fargo 2024 Healthcare Conference Location: Boston Fireside Chat: Thursday, September 5, 2024, at 9:30 a.m.
Zacks Investment Research
Aug 16, 2024
Surging Earnings Estimates Signal Upside for Harmony Bioscie...
Harmony Biosciences (HRMY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Seeking Alpha
Aug 15, 2024
Harmony Biosciences: Advancing An Expanded Pipeline
Today, we are revisiting the biopharma name Harmony Biosciences for the first time in nearly a year and a half. The company is nicely profitable thanks to its flagship product WAKIX and Harmony has a solid balance sheet as well. Harmony Biosciences has made some recent acquisitions that greatly expanded its pipeline and peak sales potential.
Zacks Investment Research
Aug 14, 2024
Can Harmony Biosciences (HRMY) Climb 25.05% to Reach the Lev...
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
